| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
2-Amino-2-cyclopentylacetic acid has been reported as a competitive inhibitor of S-adenosylmethionine synthetase, which inhibits bacterial growth. This suggests a potential target in bacterial metabolism, specifically the enzyme S-adenosylmethionine synthetase. By inhibiting this enzyme, the compound may disrupt essential cellular processes in bacteria. As a glycine derivative, it may also interact with glycine receptors or transporters, although this has not been specifically reported for this compound. Further research is needed to fully elucidate its molecular targets.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity of 2-Amino-2-cyclopentylacetic acid has been demonstrated as a competitive inhibitor of S-adenosylmethionine synthetase, leading to the inhibition of bacterial growth. This in vitro antimicrobial activity suggests its potential as a lead compound for the development of new antibacterial agents. The compound's ability to inhibit a key bacterial enzyme highlights its utility in studying bacterial metabolism. Amino acid derivatives like this one are also known to influence the secretion of anabolic hormones and fuel supply, although these effects are more associated with their use as ergogenic supplements. |
| ln Vivo |
In vivo activity of 2-Amino-2-cyclopentylacetic acid has not been well-documented. As a research chemical, it is primarily used as a building block. Its in vitro antimicrobial activity against bacteria suggests potential in vivo efficacy, but animal studies have not been reported. The compound's role as an enzyme inhibitor would need to be validated in vivo to assess its therapeutic potential. Further studies are required to determine its pharmacokinetics and pharmacodynamics in living systems.
|
| Enzyme Assay |
In vitro enzyme assays can be used to study the mechanism of action of 2-Amino-2-cyclopentylacetic acid. A typical protocol to assess its inhibition of S-adenosylmethionine synthetase would involve incubating the enzyme with varying concentrations of the compound and its substrate, ATP, and L-methionine. The production of S-adenosylmethionine is then measured using a coupled assay or HPLC. The inhibition constant (Ki) can be determined by analyzing the enzyme kinetics in the presence of different inhibitor concentrations. This assay directly measures the compound's ability to inhibit the target enzyme.
|
| Cell Assay |
Cell-based assays for 2-Amino-2-cyclopentylacetic acid would focus on its antimicrobial activity. A standard protocol is the broth microdilution assay to determine the minimum inhibitory concentration (MIC) against various bacterial strains. In this assay, serial dilutions of the compound are prepared in 96-well plates, and a standardized inoculum of bacteria is added. The plates are incubated, and the MIC is determined as the lowest concentration of compound that visibly inhibits bacterial growth. This assay is commonly used to evaluate the antimicrobial potential of new compounds.
|
| Animal Protocol |
In vivo animal experiments for 2-Amino-2-cyclopentylacetic acid are not commonly performed. If the compound were to be tested in vivo, a mouse model of bacterial infection could be used. For example, mice would be infected with a pathogenic bacterium, and then treated with various doses of the compound administered orally or intraperitoneally. Survival rates, bacterial load in organs, and histopathological changes would be assessed to determine the compound's in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Amino-2-cyclopentylacetic acid have not been characterized. As a research chemical, it is not intended for therapeutic use. Its molecular weight of 143.18 g/mol suggests it could be absorbed orally. However, no data on its absorption, distribution, metabolism, or excretion are available. The compound's stability and solubility would influence its formulation. Any pharmacokinetic studies would be necessary if the compound were to be developed further as a drug candidate.
|
| Toxicity/Toxicokinetics |
Toxicity data for 2-Amino-2-cyclopentylacetic acid is limited. As a research chemical, it is not intended for human use. Standard laboratory safety precautions should be followed when handling this compound. No specific information regarding acute toxicity, genotoxicity, or reproductive toxicity is available. Given its structural similarity to natural amino acids, it may have a low toxicity profile, but this has not been formally established.
|
| References | |
| Additional Infomation |
2-Amino-2-cyclopentylacetic acid is a synthetic glycine derivative used as a building block in peptidomimetic and small molecule synthesis. It is not a drug and has no approved therapeutic indications or clinical trial history. The compound is commercially available from various chemical suppliers for research purposes only. Its primary application is in the field of medicinal chemistry for the preparation of conformationally constrained peptides. The cyclopentyl group introduces steric hindrance, which can influence the bioactivity of the resulting molecules.
|
| Molecular Formula |
C7H13NO2
|
|---|---|
| Molecular Weight |
143.18
|
| Exact Mass |
143.094
|
| CAS # |
933-95-9
|
| PubChem CID |
224366
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
273.5±23.0 °C at 760 mmHg
|
| Flash Point |
119.2±22.6 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.497
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
10
|
| Complexity |
130
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C(C1CCCC1)N)O
|
| InChi Key |
XBPKRVHTESHFAA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H13NO2/c8-6(7(9)10)5-3-1-2-4-5/h5-6H,1-4,8H2,(H,9,10)
|
| Chemical Name |
2-amino-2-cyclopentylacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.9842 mL | 34.9211 mL | 69.8422 mL | |
| 5 mM | 1.3968 mL | 6.9842 mL | 13.9684 mL | |
| 10 mM | 0.6984 mL | 3.4921 mL | 6.9842 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
